VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Blood Cancer Journal, Published online: 02 November 2020; doi:10.1038/s41408-020-00378-zVIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Source: Blood Cancer Journal - November 2, 2020 Category: Hematology Authors: Tengteng Yu Bharat Chaganty Liang Lin Lijie Xing Boopathy Ramakrishnan Kenneth Wen Phillip A. Hsieh Andrew Wollacott Karthik Viswanathan Hedy Adari Shih-Feng Cho Yuyin Li Hailin Chen Wenjuan Yang Yan Xu Gang An Lugui Qiu Nikhil Munshi Gregory Babcock Zach Source Type: research